期刊文献+

催乳素与乳腺癌内分泌治疗耐药的研究进展 被引量:4

下载PDF
导出
摘要 乳腺癌是一种激素依赖性肿瘤。肿瘤细胞生长受体内多种激素的调控。内分泌治疗是激素受体阳性乳腺癌的主要治疗手段之一,但内分泌耐药却是导致治疗失败的主要临床原因。高催乳素水平可以增加女性患侵袭性乳腺癌的风险,催乳素通过与催乳素受体结合激活下游的信号通路影响内分泌治疗参与耐药。本文就乳腺癌内分泌耐药与催乳素的联系进行综述,相信催乳素及其受体的研究将为乳腺癌的治疗提供重要的方向。
出处 《实用肿瘤杂志》 CAS 2018年第4期387-390,共4页 Journal of Practical Oncology
  • 相关文献

参考文献2

二级参考文献26

  • 1Miron L, Negur~t L, Peptanariu D, et al. Research on aromatase gene ( CYP19A1 ) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer[J]. Rev Med Chir Soc Med Nat Iasi,2012,116 (4) :997 - 1004.
  • 2Ewertz M, Gray KP, Regan MM, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1- 98 trial[ J]. J Clin Oncol,2012,30(32) :3967 - 3975.
  • 3Hevir N, TroUt N, Debeljak N, et al. Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines [ J]. Chem Biol Interact,2011,191 ( 1-3 ) :206 - 216.
  • 4Amaral C, Varela C, Azevedo M, et al. Effects of steroidalaromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy [ J ]. J Steroid Biochem Mol Biol,2013,135(3) :51 -59.
  • 5Lin SL, Yah LY, Zhang XT, et al. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/ Akt pathways [J]. PLoS One, 2010,5 ( 2 ) : e9013.
  • 6Gambaeeiani M. Selective estrogen modulators in menopause [J]. Minerva Ginecol, 2013,65 ( 6 ) : 621 - 630.
  • 7Palacios S. Selective estrogen receptor modulators:the future in menopausal treatment [ J ]. Minerva Ginecol, 2011,63 ( 3 ) :275 - 286.
  • 8Johansson HJ,Sanehez BC, Mundt F, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer[J]. Nat Commun, 2013,4 ( 7 ) : 2175.
  • 9Larsen MS, Yde CW, Christensen IJ, et al. Carboplatin treatment of antiestrogen-resistant breast cancer ceils[ J]. Int J Oncol,2012,41 (5) : 1863 - 1870.
  • 10Nicholson S, Wright C, Sainsbury JR, et al. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and TAM failure[ J]. J Steroid Biochem Mol Biol, 1990, 37(6) :811 -814.

共引文献26

同被引文献58

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部